We are live on
!
Find out more
3C
325 Capital Portfolio holdings
AUM
$274M
1-Year Est. Return
49.96%
This Fund
S&P 500
This Quarter
Est. Return
+14.37%
1 Year Est. Return
+49.96%
3 Year Est. Return
+158.78%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$217M
AUM Growth
+$14.7M
(+7.3%)
Cap. Flow
-$5.79M
Cap. Flow
% of AUM
-2.67%
Top 10 Holdings %
Top 10 Hldgs %
94.67%
Holding
13
New
–
Increased
1
Reduced
–
Closed
1
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Lifecore Biomedical
LFCR
|
+$956K |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
DSKE
Daseke, Inc. Common Stock
DSKE
|
+$6.75M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Industrials | 37.88% |
| 2 | Healthcare | 24.87% |
| 3 | Technology | 10.4% |
| 4 | Consumer Staples | 8.41% |
| 5 | Consumer Discretionary | 5.22% |
Similar funds
ACM
MP
PP
JWM
REA
OL
HCM
BWM
325 Capital's Q1 2024 Portfolio in Review
As of Q1 2024, 325 Capital held 13 positions worth $217M, up 7.3% from $202M the previous quarter. Its ten largest holdings account for 95% of the portfolio.
325 Capital's Q1 2024 filing shows 1 increased and 1 closed positions. The largest sale was Daseke, Inc. Common Stock, an estimated $6.75M.
By sector, the portfolio is most concentrated in Industrials at 38% of assets, up from 33% a quarter earlier, followed by Healthcare and Technology.
- 325 Capital added most to Lifecore Biomedical in Q1 2024, an estimated $956K increase.
- 325 Capital fully exited Daseke, Inc. Common Stock in Q1 2024, selling an estimated $6.75M.
- 325 Capital's ten largest holdings make up 95% of its $217M portfolio in Q1 2024.
- 325 Capital opened 0 new positions and closed 1 in Q1 2024.
- 325 Capital's portfolio value rose 7.3% quarter-over-quarter to $217M.
Based on 325 Capital's 13F filing for Q1 2024, filed 15 May 2024.